生物可吸收封堵器与金属封堵器用于经导管房间隔缺损封堵:一项随机临床试验
这项多中心、非劣效性、开放标签随机临床试验纳入继发孔型房间隔缺损患者,2021年5月8日至2022年8月3日在中国10家医院入组,随机接受生物可吸收封堵器(n=116)或金属封堵器(n=114)。6个月时房间隔缺损封堵成功率生物可吸收组为96.5%(111/115) vs 金属封堵器组97.4%(111/114),组间差异-0.8个百分点(95%CI -5.0至3.7),非劣效性P<.001;2年时封堵成功率及器械相关不良事件两组无统计学显著差异,生物可吸收封堵器2年降解率约99.8%。
要点
- 6个月封堵成功率生物可吸收封堵器组96.5% vs 金属封堵器组97.4%,达到非劣效。
- 2年封堵成功率两组无统计学显著差异(94.8% vs 96.5%,P=.75)。
- 2年器械相关不良事件两组无统计学显著差异(2.6% vs 3.5%,P=.72)。
核心结论
- 生物可吸收封堵器在房间隔缺损封堵方面非劣效于金属封堵器,且2年时接近完全降解。
- 这些发现提示生物可吸收封堵器可能成为经导管房间隔缺损封堵的有价值补充选择。
研究设计与样本
- 多中心、非劣效性、开放标签随机临床试验,纳入继发孔型房间隔缺损参与者。
- 2021年5月8日至2022年8月3日在中国10家医院入组,2年随访于2024年9月结束。
- 参与者按1:1随机接受生物可吸收封堵器(n=116)或金属封堵器(n=114)。
- 230例随机参与者中,生物可吸收封堵器组1例因股静脉细小未尝试植入,最终229例(中位年龄14.1岁,IQR 7.0至37.3岁;68%为女性)。
主要发现
- 6个月房间隔缺损封堵成功率生物可吸收封堵器组96.5%(111/115) vs 金属封堵器组97.4%(111/114),组间差异-0.8个百分点(95%CI -5.0至3.7),非劣效性P<.001。
- 2年房间隔缺损封堵成功率生物可吸收封堵器组94.8%(109/115) vs 金属封堵器组96.5%(110/114),P=.75。
- 2年器械相关不良事件生物可吸收封堵器组2.6%(3/115) vs 金属封堵器组3.5%(4/114),P=.72。
- 生物可吸收封堵器2年降解率约99.8%。
关键数值与推荐
- 主要结局为6个月房间隔缺损封堵成功率,封堵成功定义为手术成功且经胸超声心动图评估残余分流直径≤2 mm。
- 2年随访时比较两组房间隔缺损封堵成功率及器械相关不良事件,并评估生物可吸收封堵器的降解情况。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The permanent metallic occluders used for atrial septal defect (ASD) closure are associated with risks of late complications and may impede access to the left atrium. Bioresorbable occluders have the potential to address these limitations but have yet to be validated in randomized clinical trials. OBJECTIVE: To evaluate whether a bioresorbable occluder is noninferior to a metallic occluder based on its efficacy and safety for transcatheter ASD closure. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, noninferiority, open-label randomized clinical trial included participants with secundum ASD. Enrollment occurred from May 8, 2021, to August 3, 2022, at 10 hospital sites in China. The 2-year follow-up period ended in September 2024. INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive a bioresorbable occluder (n = 116) or a metallic occluder (n = 114). MAIN OUTCOMES AND MEASURES: The primary outcome was the success rate of ASD closure at 6 months (closure success was defined as procedural success with a residual shunt diameter of ≤2 mm, which was assessed using transthoracic echocardiography). At the 2-year follow-up, the occluder groups were compared regarding the success of ASD closure and the device-related adverse events. The degradation profile of the bioresorbable occluder was assessed at 2 years. RESULTS: Of the 230 participants randomized, implantation was not attempted in 1 participant in the bioresorbable occluder group due to a small femoral vein, leaving 229 (median age, 14.1 years [IQR, 7.0 to 37.3 years]; 68% were female). At 6 months, the success rate of ASD closure was 96.5% (111 of 115 patients) for the bioresorbable occluder group vs 97.4% (111 of 114 patients) for the metallic occluder group (between-group difference, -0.8 percentage points [95% CI, -5.0 to 3.7]; P < .001 for noninferiority). At 2 years, there were no statistically significant between-group differences in ASD closure success (94.8% [109/115] in the bioresorbable occluder group vs 96.5% [110/114] in the metallic occluder group; P = .75), or in device-related adverse events (2.6% [3/115] vs 3.5% [4/114], respectively; P = .72). The rate of degradation at 2 years was approximately 99.8% for the bioresorbable occluder. CONCLUSIONS AND RELEVANCE: A bioresorbable occluder is noninferior to a metallic occluder for ASD closure, with near-complete degradation by 2 years. These findings suggest that a bioresorbable occluder could be a valuable addition to the options for transcatheter ASD closure. TRIAL REGISTRATION: chictr.org.cn Identifier: ChiCTR2100044408.
引用
- Ouyang W, Jiang H, Yan X, et al. Bioresorbable vs Metallic Occluders for Transcatheter Atrial Septal Defect Closure: A Randomized Clinical Trial. JAMA. 2025. PMID: 41129120. doi:10.1001/jama.2025.17639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。